Evidence map›Paper›PMID 23474128›Full record

ArticleLung cancer (Amsterdam, Netherlands)2013

K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.

Richard J Calvert, Meghana Gupta, Anna Maciag, Yih-Horng Shiao, Lucy M Anderson

Open access · greenAbstract read
In one paragraph

Article in Lung cancer (Amsterdam, Netherlands), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Therapeutic potential of NADPH oxidase 1/4 inhibitors.British journal of pharmacology · 2017
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Richard J CalvertU.S. Food and Drug Administration, MOD-1 Laboratory, 8301 Muirkirk Road, Laurel, MD 20708, USA. richard.calvert@fda.hhs.gov
Meghana Gupta
Anna Maciag
Yih-Horng Shiao
Lucy M Anderson
Frederick National Laboratory for Cancer Research · USScience Applications International Corporation (United States) · USUnited States Food and Drug Administration · US

Funding

CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

The K-ras gene is frequently mutated in lung and other cancers. K-ras protein includes two splice variants, K-ras 4A and 4B. While K-ras 4B is more widely expressed, recent evidence implicates K-ras 4A in lung tumorigenesis. We found that K-ras 4A protein has a wide range of expression in a large panel of human lung adenocarcinoma cell lines. In cell lines with mutant K-ras, but not those with wildtype K-ras, the K-ras 4A protein had a strong positive correlation with levels of cellular superoxide. We investigated whether K-ras 4A protein was involved in superoxide production, or alternatively was modulated by elevated superoxide. Experiments with small interfering RNA targeting K-ras 4A did not confirm its role in superoxide generation. However, decreasing cellular superoxide with the scavenger Tiron tended to reduce levels of K-ras 4A protein. K-ras 4A and 4B mRNA were also quantified in a number of NSCLC cell lines. 4A mRNA correlated with 4A protein only in K-ras-mutant cells. K-ras 4A mRNA also correlated with superoxide, but with no difference between cell lines with mutant or wildtype K-ras. K-ras 4B mRNA correlated with 4A mRNA and with superoxide, in both K-ras mutant and wildtype cells. The results are consistent with superoxide directly or indirectly up-regulating expression of all K-ras genes, and also increasing the stability of K-ras 4A mutant protein selectively.

Indexed as

AdenocarcinomaAdenocarcinoma of LungCarcinogenesisCell Line, TumorGene Expression Regulation, NeoplasticHumansLung NeoplasmsMutant ProteinsMutationProtein IsoformsProto-Oncogene Proteins p21(ras)RNA, Small InterferingSuperoxidesKRAS protein, humanMutant ProteinsProtein IsoformsProto-Oncogene Proteins p21(ras)RNA, Small InterferingSuperoxides

Identifiers

PMID23474128
PMCPMC3992873
OpenAlexW1988100510

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.